The National Agency for Food and Drugs Administration and
Control has raised the alarm over the circulation of suspected counterfeit
Augmentin 625mg Tabs in the country.
According to NAFDAC, the product failed short of the
labeling requirements.
The alert signed by the management of NAFDAC and titled
‘NAFDAC Alert And Sensitization Of The Public On Suspected Falsified Augmentin
625mg’ was obtained by our correspondent on the agency’s website.
NAFDAC said the suspected falsified Augmentin which was
manufactured in April 2021 would expire on April 2024.
It also noted that the batch number of the falsified drug is
562626 with a NAFDAC registration number- 04-1928.
It said “The product failed short of the labeling
requirements. No inscription “manufactured by” is written on the label -only
the address.
“Manufacturing and Expiry dates do not meet the acceptable
format. No MAS scratch number for verification.
“The logo “gsk” is
not properly positioned as on the original. The listed information indicates
the product is falsified and counterfeited.
“In view of the above, NAFDAC has notified all its
formations in the zones and 36 states of the federation including the FCT to
carry out surveillance and mop up the falsified Augmentin tablets.”
It added, “Please note that the genuine Augmentin 625mg has
legible product labeling information including date markings – expiration and
manufactured dates, batch number and NAFDAC registration number.
“NAFDAC advise to wholesalers, distributors, and pharmacies
is that medicines should be obtained from authorized/licensed suppliers,
increased vigilance is hereby encouraged within the supply chain to avoid
infiltration of the falsified product. The products’ authenticity, physical
condition and labels should be carefully checked.
“NAFDAC implores healthcare providers to ensure vigilance to
prevent the administration of falsified products to unsuspecting patients.
Members of the public in possession of the above suspected counterfeit product
are advised to discontinue sale or use and submit stock to the nearest NAFDAC
office.
“Healthcare providers and the public should notify the
nearest NAFDAC office of any information concerning the distribution, sale, and
use of the falsified version of the Augmentin product. Report any suspicion of
adverse drug reaction and substandard and falsified medicines to NAFDAC on
0800-162-3322 or email: sf.alert@nafdac.gov.ng.”
Advertise on NigerianEye.com to reach thousands of our daily users
No comments
Post a Comment
Kindly drop a comment below.
(Comments are moderated. Clean comments will be approved immediately)
Advert Enquires - Reach out to us at NigerianEye@gmail.com